BX Swiss TOP 30 CHF
1.253,34
PKT
+0,61
PKT
+0,05
%
Werbung
Analysen zu BX Swiss TOP 30 CHF-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 03.02.17 | Givaudan neutral | Kepler Cheuvreux | |
| 03.02.17 | Nestlé buy | Goldman Sachs Group Inc. | |
| 02.02.17 | Roche overweight | Morgan Stanley | |
| 02.02.17 | Roche overweight | JP Morgan Chase & Co. | |
| 02.02.17 | UBS Hold | Commerzbank AG | |
| 02.02.17 | Roche buy | Deutsche Bank AG | |
| 02.02.17 | Roche Hold | HSBC | |
| 02.02.17 | Givaudan Underperform | Bernstein Research | |
| 01.02.17 | Roche Conviction Buy List | Goldman Sachs Group Inc. | |
| 01.02.17 | Roche Hold | Baader Bank | |
| 01.02.17 | Givaudan buy | Baader Bank | |
| 01.02.17 | UBS Hold | Deutsche Bank AG | |
| 01.02.17 | Swiss Re Sell | UBS AG | |
| 01.02.17 | Givaudan Hold | Deutsche Bank AG | |
| 01.02.17 | Givaudan overweight | JP Morgan Chase & Co. | |
| 01.02.17 | Givaudan Sell | Citigroup Corp. | |
| 01.02.17 | Holcim overweight | Morgan Stanley | |
| 01.02.17 | Holcim kaufen | HSBC | |
| 31.01.17 | Nestlé overweight | JP Morgan Chase & Co. | |
| 31.01.17 | UBS Underperform | BNP PARIBAS | |
| 31.01.17 | Novartis Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 30.01.17 | UBS overweight | Barclays Capital | |
| 30.01.17 | UBS overweight | Morgan Stanley | |
| 30.01.17 | UBS Neutral | JP Morgan Chase & Co. | |
| 30.01.17 | Novartis Neutral | JP Morgan Chase & Co. | |
| 30.01.17 | Novartis Neutral | UBS AG | |
| 30.01.17 | Novartis buy | HSBC | |
| 30.01.17 | UBS Neutral | Goldman Sachs Group Inc. | |
| 27.01.17 | UBS Outperform | BMO Capital Markets | |
| 27.01.17 | UBS buy | Citigroup Corp. | |
| 27.01.17 | UBS buy | Citigroup Corp. | |
| 27.01.17 | UBS Neutral | Credit Suisse Group | |
| 27.01.17 | UBS Outperform | RBC Capital Markets | |
| 27.01.17 | Swiss Re buy | Goldman Sachs Group Inc. | |
| 27.01.17 | UBS overweight | Barclays Capital | |
| 27.01.17 | UBS buy | S&P Capital IQ | |
| 27.01.17 | UBS buy | Baader Bank | |
| 27.01.17 | UBS Hold | Commerzbank AG | |
| 26.01.17 | ABB (Asea Brown Boveri) overweight | Morgan Stanley | |
| 26.01.17 | Novartis Underweight | Morgan Stanley |